Additional Relevant Details
INMARK™ study will investigate the effect of OFEV on the rate of change of ECM turnover biomarkers compared to placebo in patients with IPF. Two thirds of patients will be treated with placebo for the first 12 weeks of the trial; one third of the patients will receive treatment with nintedanib (150 mg twice daily). Following the 12 week placebo controlled period, all patients in the trial will continue further treatment with nintedanib for 40 weeks. This will allow active treatment for patients previously on placebo. The study aims to include 350 patients across Australia, Asia, Europe and North America.